Bell Potter Keeps Buy on Oneview Healthcare, Cuts Revenue Forecast
Bell Potter analyst Martyn Jacobs cut Oneview Healthcare's second-half revenue forecast by almost 30% and its target price by 29%, while keeping a buy rating.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Bell Potter analyst Martyn Jacobs has kept a buy rating on Oneview Healthcare, an ASX-listed healthcare-software provider, despite its slow revenue generation, Market Talk reports. He lowered his second-half revenue forecast by almost 30%, to 7 million euros, which implies annual revenue growth of only 4.1%.
Jacobs said the pace of Bedside Hub TV contract deliveries is encouraging, but he told clients the real test is deployment and recurring fee generation. His target price falls 29% to A$0.30. Shares rose 7.7% to A$0.14.
why it matters
For investors, the note is a mixed signal: the analyst still sees upside, but the revenue outlook is clearly more modest. According to Jacobs, the stock will be judged on how fast the product is deployed and how much recurring fee income it generates.
tags
instruments
sources
- Oneview Keeps Its Bull Despite Slow Revenue Generation — Market Talk, 28 October 2026 at 03:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗